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Neuropilins (NRPs) are receptors for the major chemorepul-
sive axonal guidance cue semaphorins (Sema). The interaction
of Sema3A/NRP1 during development leads to the collapse of
growth cones. Here we show that Sema3A also induces death of
cultured cortical neurons through NRP1. A specific NRP1
inhibitory peptide ameliorated Sema3A-evoked cortical axonal
retraction and neuronal death. Moreover, Sema3A was also
involved in cerebral ischemia-induced neuronal death. Expres-
sion levels of Sema3A and NRP1, but not NRP2, were signifi-
cantly increased early during brain reperfusion following tran-
sient focal cerebral ischemia. NRP1 inhibitory peptide delivered
to the ischemic brain was potently neuroprotective and pre-
vented the loss of motor functions in mice. The integrity of the
injected NRP1 inhibitory peptide into the brain remained
unchanged, and the intact peptide permeated the ischemic
hemisphere of the brain as determined usingMALDI-MS-based
imaging. Mechanistically, NRP1-mediated axonal collapse and
neuronal death is through direct and selective interaction with
the cytoplasmic tyrosine kinase Fer. Fer RNA interference effec-
tively attenuated Sema3A-induced neurite retraction and neu-
ronal death in cortical neurons. More importantly, down-regu-
lation of Fer expression using Fer-specific RNA interference
attenuated cerebral ischemia-induced brain damage. Together,
these studies revealed a previously unknown function of NRP1
in signaling Sema3A-evoked neuronal death through Fer in cor-
tical neurons.
Injured central nervous system axons have a very limited
capacity to regenerate due to the presence of a plethora of
growth inhibitory ligands secreted from oligodendrocytes/my-
elin, reactive astrocytes, and fibroblasts in the damaged tissue
(1–6). Neurons must integrate this multitude of inhibitory
molecular cues, generated as a result of cortical damage, into a
functional response.More often than not the response is one of
growth cone collapse, axonal retraction, and neuronal death.
Therefore, chemorepulsive factors likely contribute either
directly or indirectly to neuronal death in the injured adult
brain (7–10). Indeed, the expression of Sema3A, a major che-
morepulsive factor, has been reported in several brain injury
models, such as peripheral nerve injury, spinal cord injury, cere-
bral ischemia, and Alzheimer disease (1, 3, 11–16). In addition,
Sema3A expression has been shown to increase vascular per-
meability, whichmay indirectly contribute to neuronal damage
(17).
The biological activities of Sema3A during development are
complex and context-dependent. Although best known for its
role as an axonal growth cone repellent, Sema3A also serves as
a chemoattractant during cortical layer development by guid-
ing the radial migration of layer II/III cortical neurons (18) and
the growth of apical dendrites toward the pial surface (19). In
contrast, Sema3A is also important in stereotyped pruning of
long hippocampal axon branches (20), causing dorsal root gan-
glia axon retraction (21), and evoking apoptosis of sensory neu-
rons (22–24) possibly through activating apoptotic pathways
involving PlexinA3 receptor and mitogen-activated protein
kinases (25, 26).
The cellular receptors for semaphorins are neuropilins
(NRP1 andNRP2)2 (27, 28). Structurally, bothNRPs contain an
extracellular domain of two CUB motifs, adjacent to two
domains with homology to coagulation factors V and VIII; a
MAM domain; a single transmembrane domain; and a short
intracellular domain of 39 amino acids lacking any known sig-
naling motifs (27–29). The structural domain required for
Sema3A/NRP1 interaction has been characterized (30), and
several specific polypeptides antagonizing Sema3A IgGdomain
and NRP1 MAM domain have been found to inhibit Sema3A/
NRP1-mediated inhibition of axonal outgrowth in vitro (31).
NRP1 is amultifunctional receptor, whichmediates activities
of structurally distinct ligands during development of the heart,
vasculature, and neuronal system (32). An indication of the
importance of NRP1 function in adult mice brain came from
our recent discovery that NRP1 expression was transcription-
ally regulated by the apoptosis-inducing transcription factor
E2F1 (33). Activation of E2F1 causes neuronal death during
* This workwas supported byHeart and Stroke Foundation of Ontario Grants
NA5393 and T5760 and by Canadian Institutes of Health Research Grant
CCI85680 (to S. T. H.).
□S The on-line version of this article (available at http://www.jbc.org) contains
supplemental Figs. S1–S3 and “Materials and Methods.”
1 Towhom correspondence should be addressed: NRC Inst. for Biological Sci-
ences, National Research Council Canada, Bldg. M54, 1200 Montreal Rd.,
Ottawa, Ontario K1A 0R6, Canada. Tel.: 613-993-7764; Fax: 613-941-4475;
E-mail: sheng.hou@nrc-cnrc.gc.ca.
2 The abbreviations used are: NRP1 and -2, neuropilins 1 and 2; MALDI-MSI,
matrix-assisted laser desorption/ionization-mass spectrometry imaging;
TOF, time of flight; MCAO, middle cerebral artery occlusion; PI, propidium
iodide; RNAi, inhibitory RNA; Sema3A, semaphorin 3A; TTC, 2,3,5-triphen-
yltetrazoliumchloride; TUNEL, terminal deoxynucleotidyltransferase dUTP
nick end labeling; DIV, days in vitro; NMDA, N-methyl-D-aspartic acid; IP,
immunoprecipitation.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 285, NO. 13, pp. 9908–9918, March 26, 2010
© 2010 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.
9908 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 285•NUMBER 13•MARCH 26, 2010
cerebral ischemia (34, 35). In this study, the neuroprotective
effects of blocking NRP1 interaction with Sema3A were inves-
tigated and the cytoplasmic tyrosine kinase Fer was determined
as a downstream effecter for NRP1-mediated death signal
transduction.
EXPERIMENTAL PROCEDURES
Cerebral Ischemia Produced by MCAO—All procedures
using animals were approved by the local Animal Care Com-
mittee (Protocol 2007.10). C57BL/6 mice (20–23 g) were
obtained from Charles River (St Foie, Quebec). Under tempo-
rary isoflurane anesthesia, mice were subjected to middle cere-
bral artery occlusion (MCAO)using an intraluminal filament as
previously described (36, 37). After 1 h of MCAO, the filament
was withdrawn, and blood flow was restored to basal levels, as
assessed by laser Doppler flowmetry. Wounds were sutured.
The body temperature of experimental mice was monitored
before and after the MCAO surgery using a rectal probe and
was maintained at 37 °C using a heating pad and lamp. After 2,
4, 8, and 24 h and 2–7 days of reperfusion, mice were sacrificed.
In preliminary experiments to verify a consistent stroke proce-
dure, measurements of blood pressure, blood gases, and pH
were also performed as previously described in both peptide-
treated and small interference RNA-treated mice (38).
Peptide Synthesis and Stereotactic Microinjection—NRP1
inhibitory polypeptide 1 (NRP1 inh Pep1, targeting Sema3A
IgG domain, HAVEHGFMQTLLKVTLE), NRP1 inhibitory
polypeptide 2 (NRP1 inh Pep2, targeting NRP1 MAM domain,
FWYHMSGSHVGTLRVKLP), and a sequence-scrambled con-
trol peptide (Control Pep, LKHEVMFLQETVTHLAG) were
commercially synthesized (Genscript Corp., Piscataway, NJ) to
a purity of 95% using high-performance liquid chromatogra-
phy. Peptides (both the NRP1 inhibitory peptides and the con-
trol peptide)were dissolved in 0.01Mphosphate-buffered saline
to a concentration of 2 mg/ml, and 5 l was injected into the
lateral ventricles (intracerebroventricularly) through stereotac-
tical injection (Bregma, 0.9-mm lateral, 0.1-mm posterior, and
3.0-mm ventral) using a Hamilton microsyringe at 1 l/min
at a dosage of 0.4 mg/kg.
MALDI-MSI of NRP1 Peptides—Matrix-assisted laser de-
sorption/ionizationmass spectrometry imaging (MALDI-MSI)
was used to detect distribution of NRP1 inhibitory peptides in
the injected mouse brain as previously described (39, 40). Spe-
cifically,mice receiving unilateralMCAOand intracerebroven-
tricular injections of the NRP1 inhibitory peptide were sacri-
ficed 1 and 6 h after reperfusion. Entire intact mouse brains
were removed carefully and flash frozen in liquid N2. 10-m
coronal sections were cut using a cryostat, and the sections
FIGURE 1. NRP1 inhibitory peptide ameliorates Sema3A-mediated inhibition of neurite outgrowth, growth cone collapse, axonal damage and neu-
ronaldeath.Cortical brain tissue explantswere culturedona collagenmatrix gel for 2–5DIV, followedby treatmentwithbrain-derivedneurotrophic factor (50
ng/ml), or Sema3A (5 g/ml) with or without pre-treatment with the NRP1 inhibitory peptide1 or the control peptide (20 M) (a–d). Neurite outgrowth, as
indicated by solid arrows in a, was measured using ImageJ on digitized images and plotted in b. Growth cone collapse induced by Sema3A treatment was
visualizedusingphalloidin labeledwithAlexa 488, and the representative images are shown in c. Increasednumberof collapsedgrowth coneandamelioration
of growth cone collapse by NRP1 inhibitory peptide1 were quantified and plotted in d. To determine Sema3A-induced neuronal death, cortical neurons were
cultured in the B27 and N2 supplemented neural basal medium for 7 DIV. These cells were untreated (e), treatedwith Sema3A (f), pretreated using the control
peptide (g), NRP1 inhibitory peptide1 (h), or NRP1 inhibitory peptide2 (i). After 8-h incubation, PI (1g/ml) was added to the culture wells and incubated with
cells for 30 min at 37 °C. Cells were examined under a florescence microscope to detect PI (e–i). The percentage of PI-positive cells were counted per 40
microscopic objective field and plotted in j. Changes in neurite morphology and length were shown in k–n. Solid arrows in l indicate dead cells, whereas open
arrows in k–n indicate live cells under the phase-contrast microscope. Error barsS.E. **, statistical significance by one-way analysis of variance and further
post hoc test for significant groups using Tukey’s test with p 0.01. Data were from at least three independent repeats. Scale bars 20 m.
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were mounted onto pre-coated 41-  41-mm stainless steel
MALDI slideswith a spray containing 10mg/ml 2,5-dihydroxy-
benzoic acid DHB in 30%MeOH/H2O. EachMALDI slide con-
tained 300 l of spray. The brain sections were then re-hy-
drated carefully with ddH2O mist. The mist effectively created
a fog of moisture and provided a means to re-hydrate the sam-
ple without causing low molecular weight compound to shift.
The re-hydrated sample was then sprayed with an additional
300 l of 10 mg/ml 2,5-dihydroxybenzoic acid in 30% MeOH/
H2O thus sandwiching the brain tissue sections between two
layers ofmatrix.MALDI imaging was performed on anApplied
Biosystems 4800 MALDI TOF/TOF. All analysis was done in
positive ion using reflectron mode to obtain a high spectral
resolution. The ionization was initiated with a third harmonic
Nd:YAG pulse, and 75–150 spectra were then summed to pro-
vide 1 pixel on the image. The pitch of the pixelswas between 75
and 100 m. The instrument was controlled via a 4000 Series
Imaging (Novartis, ABI). Data analysis and visualization were
done using TissueView (ABI, Novartis).
Fer RNAi Design, Transfection, and Intracerebroventricular
Delivery in the Brain—StealthTM RNAi molecules were chem-
ically modified, and blunt-ended, 25-mer double-stranded
duplexes with minimal off-target effect were demonstrated by
the manufacturer (Invitrogen). Chemically modified RNAi
molecules (StealthTM RNAi) targeting three different re-
gions of mouse Fer kinase were designed and synthesized
commercially by Invitrogen. A sequence-scrambled negative
control StealthTM RNAi duplex was also commercially synthe-
sized by Invitrogen. Details of methods used, confirming the
specificity of Fer, are described in the supplemental “Materials
andMethods” (additional experimental procedures can also be
found in the supplemental “Materials and Methods”).
RESULTS
Sema3A Induces Neurite Retraction and Neuronal Death
through NRP1 in Vitro—To determine the role of Sema3A/
NRP1 in adult cortical neurons, a synthetic polypeptide specif-
ically inhibitingNRP1/Sema3A interaction (31) was chemically
synthesized and used on cultured 7 DIV mouse cortical neu-
rons. These neurons were treated with active Sema3A protein,
which effectively induced significant neurite retraction and
growth cone collapse in cultured cortical explants grown from
embryonic (15 days) mice on a collagen matrix gel set on glass
coverslips coated with poly-L-lysine (Fig. 1, a–d). The NRP1
inhibitory peptide1 effectively alleviated Sema3A-mediated
inhibition of neurite outgrowth and growth cone collapse
(Fig. 1, a–d). In contrast, brain-derived neurotrophic factor,
serving as a positive control, significantly enhanced neurite
outgrowth with fully extended growth cones shown by phalloi-
din staining (Fig. 1, a–d). These data demonstrated that NRP1
inhibitory peptide1 was effective in ameliorating Sema3A-me-
diated inhibition of neurite outgrowth.
We next sought to examine the effects of Sema3A on cortical
neurons. Cortical cultureswere deemedmature by 7DIVdue to
their responsiveness to glutamate-induced excitotoxicity
(supplemental Fig. S1). Interestingly, cortical neurons at 7 DIV
treatedwith Sema3A resulted in neuronal death, as indicated by
the increased number of propidium iodide (PI)-positive cells
(Fig. 1, f and j). Sema3A-induced neuronal deathwas blocked by
NRP1 inhibitory peptide1 (a peptide targeting the IgG domain
of Sema3A) as compared with those neurons treated with the
scrambled control peptide (Fig. 1, g and j). To determine the
specificity of neuroprotection caused by blocking Sema3A/
NRP1 interaction, NRP1 inhibitory peptide2 (targeting the
MAMdomain of NRP1) was also used. As shown in Fig. 1 (i and
j), NRP1 inhibitory peptide2 was also significantly neuropro-
tective. Neurites in Sema3A-treated cortical neurons appeared
short and fragmented as shown in Fig. 1l in comparison with
the non-treated (Fig. 1k), and the NRP1 inhibitory peptide1-
and 2-treated neurons (Fig. 1,m and n). Together, these studies
demonstrated that Sema3A caused axonal damage and neuro-
nal death of cortical neurons through interaction with NRP1 in
vitro and that the synthetic NRP1 inhibitory peptides are spe-
cific and effective in preventing Sema3A toxicity.
Increased Expression of Sema3A and NRP1 in Ischemic
Mouse Brain—To determine whether Sema3A/NRP1 are also
involved in neuronal death in ischemic mouse brain in vivo,
Western blotting was performed on mouse brain tissue sub-
jected to MCAO. The expression of NRP1 increased 2 h after
reperfusion, and its level remained high in the ischemic brain
8 h following reperfusion (Fig. 2, a and b). In contrast, the
expression level of NRP2 did not change appreciably at 2 and
FIGURE 2.Early induction in theexpressionof Sema3AandNRP1 in ische-
mic mouse brain. Brains were removed from mice subjected to 1-h MCAO
followed by 2-, 4-, or 8-h reperfusion. Proteins were isolated from both the
contralateral (C) and ipsilateral (I) side of the brain. Western blotting was per-
formed on 25 g of brain protein to detect the expression of NRP1 (a), NRP2
(c), and Sema3A (e). The expression levels of NRP1, NRP2, and Sema3A were
quantified against GAPDH (b, d, and f, respectively). A representative gel of at
least three repeats is presented. **, statistical significance comparedwith the
sham-operated group by one-way analysis of variance and further post hoc
test for significant groups using Tukey’s test with p 0.01.
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4 h after reperfusion but did demonstrate an increase 8 h fol-
lowing reperfusion (Fig. 2, c and d), indicating a late response of
NRP2 in comparison with NRP1. Double immunostaining of
brain sections showed that NRP1 expression was induced in
neurons in response to ischemia (supplemental Fig. S2a),
whereas NRP2 expression was barely detectable and only
appeared along the lectin-positive microvessel wall (supple-
mental Fig. S2b). The expression of secreted Sema3A was also
increased in extracellular space (supplemental Fig. S2c) on the
ipsilateral side of the ischemic brain (Fig. 2, e and f).
NRP1 Inhibitory Peptides Are Neuroprotective in Vivo—
Based on the observation that Sema3A/NRP1 expression
increased early in the ischemic brain, we hypothesized that
inhibition of Sema3A/NRP1 is neuroprotective. NRP1 inhibi-
tory peptide1 and -2, and the control peptide, were stereotaxi-
cally injected into the cerebral ventricles of mouse brains 1 h
NRP1Mediates Neuronal Death
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prior to MCAO followed by reper-
fusion for 24–168 h (n  9 for
NRP1 inhibitory peptides; n  11
for the NRP1 control peptide).
The body temperature before
and after peptide injection, and
during and after MCAO, were
monitored using a rectal probe and
maintained at 37  2.5 °C. Body
temperatures were found to be not
significantly different between the
NRP1 inhibitory peptides and
NRP1 sequence-scrambled con-
trol peptide-injected mice. The
body weight of these mice was also
measured, which was at 23  2 g
before surgery and 20  2 g at the
time of sacrifice. No significant dif-
ference in weight loss occurred
among the treatment groups, sug-
gesting these peptides neither affect
body temperature nor exacerbate
body weight loss.
First, to determine whether the
injected peptide maintained its
integrity in the brain and to visualize
the distribution of the injected pep-
tide in the parenchyma, brain sec-
tions (10-m thickness) were sub-
jected to MALDI-MSI using the
method as described under “Exper-
imental Procedures.” As shown in
Fig. 3a, both NRP1 inhibitory pep-
tide1 and the control peptide were
found mostly along the injection
needle tract (arrow in Fig. 3a) and in
the lateral ventricles after 1-h
MCAO. In contrast, after 6-h reper-
fusion, NRP1 inhibitory peptide and
the control peptide signals were
widely distributed in the ischemic
side of the brain (Fig. 3b). MALDI-
MSI analysis of the ischemic side of
the brain showed that the injected
FIGURE 3. Inhibition of NRP1/Sema3A interaction provides neuroprotection during cerebral ischemia.Micewere injectedwith the control peptide
or the NRP1 inhibitory peptide stereotactically into the lateral ventricles 1 h prior to a 1-h MCAO, followed by various reperfusion time. After 1-, 6-, and
24-h reperfusion, mice were killed and the brains were removed. Fresh frozen coronal brain sections (10m in thickness) were sectioned for MALDI-MSI
(a and b; 1- and 6-h reperfusion, respectively) to demonstrate the increased dissemination of the injected peptide in the brain parenchyma. Arrows in
a indicate the injection site and the presence of high level of the peptide along the needle track at 1 h after reperfusion. At 6 h after reperfusion, as shown
in b, both the injected NRP1 inhibitory peptide1 and the control peptide were widely distributed in the parenchyma on the ischemic side of the brain
(ipsi  ipsilateral side; contra  contralateral side). Total ion chromatograph of brain tissue from the boxes indicated in b (the top panel) depicts the
spectrum of the NRP1 inhibitory peptide1 (m/z 1952), as well as the Na (m/z 1975) and K (m/z 1991) ionized forms of the injected peptide (c). Brain
infarction was measured using both a spectrophotometric-based method detecting soluble TTC color intensities extracted from the ischemic brains
after 24-h reperfusion (d), and by staining the 2-mm thick coronal brain sections using TTC (e). Lane 1 in e shows a representative image of serial coronal
brain sections treated with the control peptide; lanes 2 and 3 show representative images of brain infarctions from the NRP1 inhibitory peptide1- and
2-treated mice. During reperfusion, two motor behaviors were measured, including the forepaw grip strength test (f) and the six-point neurological
deficit scores in turning behavior (g). Symbols in panels f and g are F is for the control peptide, f for NRP1 inhibitory peptide1, and Œ for NRP1 inhibitory
peptide2. The total number of mice used were n 11 for the control peptide-treated and n 9 for both NRP1 inhibitory peptide1- and 2-treated mice.
Error bars  S.E. Statistical analysis was performed to compare the control peptide and the NRP1 inhibitory peptide-treated brains using the
non-parametric Mann-Whitney U test with ** indicating statistically significant at p  0.01.
FIGURE 4. Neuronal protection conferred by NRP1 inhibitory peptide. MCAO mouse brains injected
with the control peptide or the NRP1 inhibitory peptide1 were frozen-fixed and serially sectioned. Immu-
nostainings for NeuN, III-tubulin, and Iba1 (a) and double immunostaining with TUNEL and MAP2 were
performed to show changes in NeuN positive neurons, microtubules in axons, the activated microglial
cells and neuronal death in the ischemic brain, respectively (b). The numbers of NeuN-positive cells were
counted from high resolution digital images (1300 1030 pixels) taken from in the ischemic cortex under a
40  objective and plotted as shown in c. The intensity of III-tubulin immunostaining was measured on
digitized images taken from ischemic brains using the ImageJ software. An arbitrary intensity unit was used to
show the relative changes inIII-tubulin intensity in the core andperi-infarct area of the brain (d). The intensity
of Iba1 staining was also measured using the same method and shown in e. Brain sections adjacent to those
used for NeuN staining were subjected to TUNEL and MAP2 double immunostaining (b). The number of
TUNEL-positive cells per 40 objective field were counted and plotted in f. Error bars  S.E. Statistical
significance was determined by theMann-Whitney U test using data from at least three independent repeats.
**, p 0.01. Scale bars 50 m.
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NRP1 inhibitory peptide1 was still intact with amolecularmass
of 1954 Da matching the expected molecular mass of the orig-
inal synthesized polypeptide (Fig. 3c). Na and K adducts of
theNRP1 inhibitory peptide1were also detectedwithmasses of
1978 and 1992 Da, respectively, which were higher than the
adduct-free NRP1 inhibitory peptide1.
Secondly, having established the fact that injected peptides
were intact and effectively disseminated into the ischemic side
of the brain, a series of experiments were performed to deter-
mine the neuroprotective effect of NRP1 inhibitory peptide. As
shown in Fig. 3 (d–g), the NRP1 inhibitory peptide1 and -2
provided significant protection to MCAO-induced brain
damage in comparison to the brain injected with the NRP1
control peptide, as measured by extraction of soluble TTC and
quantification using a spectrophotometric-based measure-
ment method (Fig. 3d, p  0.01). TTC staining of 2-mm thick
brain coronal sections was also shown in Fig. 3e to indicate the
area of infarction. The neuroprotection by the NRP1 inhibitory
peptide correlated with the significant improvement of motor
functions as measured by 1) the forelimb grip strength test,
which measures muscle strength and neuromuscular integra-
tion relating to the grasping reflex in the forepaws (Fig. 3f) and
2) a better performance in an expanded six-point neurological
deficit turning behavior test (Fig. 3g). NRP1 inhibitory pep-
tide1- and -2-treated mice performed significantly better after
6-h reperfusion (n  9) in these tests compared with mice
treated with the NRP1 control peptide (n 11) (Fig. 3, f and g).
The improvement of neurological functions was maintained at
all the time points tested for up to 7 days after MCAO.
Finally, to validate that neurons were indeed protected by
the NRP1 inhibitory peptide, immunostaining was per-
formed on fixed brain sections. Significant reduction in III-
tubulin staining occurred in neurons located in the infarct core
of brains treated with the control peptide. In contrast, the
expression level of III-tubulin was not significantly reduced in
the NRP1 inhibitory peptide1-treated brain (n 3, Fig. 4, a and
d), suggesting protections to the neurite network and neurons.
Correspondingly, the number of NeuN-positive neurons in the
infarct core of NRP1 inhibitory peptide1-treated ischemic
brains was also significantly higher than those in the control
peptide-treated brain (n  3, Fig. 4, a and c), suggesting that
blocking Sema3A/NRP1 directly protected neurons during
ischemia. The number of TUNEL-positive cells was also
reduced significantly in NRP1 inhibitory peptide1-treated
brains confirming that blocking Sema3A/NRP1 interaction
reduced neuronal death (Fig. 4, b and f). To exclude the possi-
bility that NRP1 inhibitory peptide1 may have an anti-inflam-
matory effect, immunostaining for activated microglia (anti-
body to Iba1 (Fig. 4, a and e)) was performed that demonstrated
no significant changes in the levels of Iba1 expression in the
infarct core or its surrounding peri-infarct tissue between the
control and NRP1 inhibitory peptide1-treated mouse brains.
These observations further support the idea that NRP1 directly
mediates neuronal death in ischemic brain.
Sema3A and NRP1 Inhibitory Peptide Do Not Affect NMDA-
mediated Intracellular Calcium Influx into Neurons—To
address themechanism by whichNRP1 evokes neuronal death,
and to exclude the possibility that NRP1 inhibitory peptide-
mediated neuroprotection was dependent of NMDA receptor
function, we measured intracellular calcium ([Ca2]i) changes
in neurons, which are stimulated in response to NMDA activa-
tion. [Ca2]i influx in cortical neurons treated with Sema3A or
NRP1 inhibitory peptide1, was measured using a Fura-2-based
ratiometric measurement method as we previously described
(36). Sema3A andNRP 1 inhibitory peptide alone did not evoke
changes in [Ca2]i influx, nor did they affect NMDA-induced
[Ca2]i influx (Fig. 5, a and b), excluding the possibility that
NRP1 inhibitory peptide-mediated neuroprotection was
through alteration of Ca2 channel functions during gluta-
mate-induced excitotoxicity. In addition, early and rapid acti-
vation of pCaMKII following ischemia in response to gluta-
mate-mediated [Ca2]i influx was also not affected by NRP1
FIGURE 5.NRP1 inhibitorypeptide1 andSema3Aproteinhasnoeffect on
[Ca2]i in cortical neurons. The effect of 5 g/ml Sema3A (a) and 20 M
NRP1 inhibitory peptide 1 (b) on [Ca2]i was determined by a ratiometric
measurement of [Ca2]i using Fura-2 following procedures as described
under “Experimental Procedures.” [Ca2]i concentration was represented by
the ratio of fluorescent intensity between the two wavelengths of R340/380 of
Fura-2 florescence. KCl (45 mM) and NMDA (100M) were used as controls to
induce neuronal responses. Data were obtained from at least three indepen-
dent experiments and the average of at least three experiments was plotted
in a and b. Lines in a and b represent the averaged concentrations of [Ca2]i.
NRP1 inhibitory peptide1-treated and control peptide-treated ischemic
brains were also collected for Western blotting to detect [Ca2]i-evoked
changes in pCaMKII (c). GAPDH protein was used as an internal loading
control.
NRP1Mediates Neuronal Death
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inhibitory peptide treatment (Fig. 5c), further supporting the
fact that blocking Sema3A/NRP1 interaction did not affect
[Ca2]i. This result demonstrates that Sema3A/NRP1 signaling
is independent of NMDA receptor functions.
Fer Directly and Selectively Interacts with NRP1 in Ischemic
Mouse Brain—To identify the intracellular mediators of NRP1
signaling in neuronal death, immunoprecipitation (IP) was per-
formed against NRP1 and NRP2 to identify molecules that
directly and selectively interact with NRP1 during death signal-
ing. The IP products derived from200g of total brain proteins
were subjected toWestern blotting against neuropilin-interact-
ing proteins, CDK5, Plexin A1, TCGAP, Fer, and Fer down-
stream-interacting protein, Cortectin (Fig. 6a; Cortectin is not
shown). Surprisingly, only Fer (a cytoplasmic non-receptor
tyrosine kinase) showed a selective association with NRP1, but
not NRP2, in the IP products derived from the normal and
ischemic mouse brain (Fig. 6, a and b). Next, we tested the
hypothesis that theNRP1 inhibitory peptide1 treatment during
MCAO would alter the level of association between NRP1
and Fer. Indeed, as shown in Fig. 6 (c and d), Western blot-
ting of IP products against NRP1 showed that MCAO caused
a 1-fold induction of association of Fer with NRP1 (Fig. 6c,
top panel, and panel d), while NRP1 inhibitory peptide1
reduced Fer association with NRP1 in the ischemic brain by
1-fold (Fig. 6c, bottom panel, and panel d). Importantly,
NRP2 did not interact with Fer either in the normal brain or
in the ischemic brain (Fig. 6, a and b). Because the expression
level of Fer in the ischemic brain did not change as seen on
Western blot (Fig. 6, e and f), it is argued that it is the amount
of association of existing Fer with NRP1 that is critical for
NRP1 signal transduction.
Experiments were also performed to determine that the
distal part of the NRP1 C-terminal domain is responsible for
binding with Fer. The middle region of the cytoplasmic
domain of NRP1 and NRP2 shares a high degree of homology
in amino acid sequences. However, this region of high
homology is not responsible for Fer binding. Using the dele-
tion mutation studies, we found that the domain responsible
for Fer binding is located within the last 18 amino acids
toward the extreme C terminus of NRP1 where there is very
low amino acid sequence homology between NRP1 and
NRP2 (supplemental Fig. S3). Together with previous
reports that overexpression of Fer caused death of non-neu-
ronal cells and inhibited axonal outgrowth in neurons (41,
42), our studies strongly suggest that Fer interaction with
NRP1 may lead to neuronal death.
FIGURE 6.NRP1directly and selectively interactswith Fer in ischemic brains. a, 200g of proteins fromnormalmouse brains were subjected to IP against
NRP1orNRP2. Equal amounts of IP productswere subjected toWesternblotting todetectNRP1orNRP2 associationwith neuropilin-interactingprotein, CDK5,
PlexinA1, TCGAP, andFer (a). In the IP reaction, a reactionwithout primary antibodywasused as anegative control (a). Todetermine changes in Fer association
withNRP1duringMCAO, ischemicbrainswere separated into contralateral (C) and ipsilateral (I) sides (b). Proteins frombrain tissuewere subjected to IP against
NRP1 or NRP2. Western blotting was performed to detect Fer and IgG (as an internal control) as shown in b. The ischemic brains (200g) from both the NRP1
inhibitory peptide1-treated and the control peptide-treated mice were also subjected to IP against NRP1 (c). Western blotting was performed on these IP
products to detect changes in Fer associationwithNRP1. IgGwas used as a loading control. The intensities of the Fer band from two independent repeatswere
measured and quantified against those of the control peptide-treated brains shown in d. Total brain lysates were also subjected toWestern blotting to detect
the level of total Fer with GAPDH as an internal loading control (e). Densitometry measurements of band intensities were normalized against that of the
sham-operated brain (f).
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Down-regulation of Fer Expression Confers Neuroprotection
against Sema3A Toxicity in Vitro—To demonstrate the direct
role of Fer in mediating Sema3A/NRP1 response, a specific
RNAi to Fer was designed and transfected in 7 DIV cortical
neurons followed by treatment with Sema3A. As shown in Fig.
7 (a and b), Fer RNAi, but not the negative control RNAi, sig-
nificantly reduced the Fer expression level in cortical neurons
after 36 and 48 h. Interestingly, Fer RNAi-treated cortical neu-
rons after 36 h in response to Sema3A (5 g/ml, for 24 h)
showed longer neurites and less neuronal death (PI-positive
cells) when compared with the non-treated control and the
negative control RNAi-treated neurons (Fig. 7, c–g). At least
300 cells and their neurites weremeasured from three indepen-
dent experiments. These data demonstrate that Fer is directly
involved in Sema3A/NRP1-mediated neuronal death.
Down-regulation of Fer Expression Is Neuroprotective against
MCAO in Vivo—To further investigate whether Fer is an inte-
gral part of the signal transduction pathway in response to
Sema3A-mediated neuronal death, a specific RNAi to Fer was
used to down-regulate the expression of Fer during cerebral
ischemia in mouse brain. The aim was to determine whether
the reduction in Fer expression is neuroprotective. Fer expres-
sion is abundant in mouse brain as shown in Fig. 6e and Fig. 8b
(first lane). Injection of chemically modified StealthTM Fer
RNAi in combination with invivofectamineTM transfection re-
agent allowed for efficient down-regulation of Fer protein level
(more than 1-fold in reduction) inmouse brain between 48 and
72 h after injection (Fig. 8, a–c), whereas the control negative
RNAi did not have any effect on the level of Fer expression (Fig.
8b, lower panel).
Based on the knockdown profile
of Fer RNAi, mice were injected
with Fer RNAi (n  7) or the con-
trol negative RNAi (n 7) for 48 h
prior to the 1 h MCAO and 24 h
reperfusion (Fig. 8d showing the
experimental schema). Knocking
down Fer expression using RNAi
significantly reduced brain infarc-
tion size after 24-h reperfusion in
comparison with the control nega-
tive RNAi-treated group (Fig. 8e).
Specifically, Fer RNAi-treated brains
showed a 23% reduction in infarct
size compared with the control
RNAi-treated group, which strongly
suggests that the reduction in Fer
expression is neuroprotective. Func-
tionally, Fer RNAi-treated mice had
amuch better preservation ofmotor
function as demonstrated by the
significantly better forepaw grip
strength scores (Fig. 8f) and neuro-
logical deficit scores (Fig. 8g) at 6-
and 24-h reperfusion time points.
The neuroprotective effect of Fer
knockdown was confirmed by im-
munohistochemical staining and
TUNEL analysis (Fig. 9). MCAO caused a significant induction
in the number of TUNEL-positive nuclei in the ischemic core in
the control negative RNAi-treated mice (arrows in Fig. 9, a and
i). Correspondingly, neurons in this area appeared to have a
shrunkenmorphology, reduced numbers, and a low intensity of
staining for NeuN (open arrows in Fig. 9, c and j). In contrast,
Fer RNAi-treated mouse brains had significantly fewer
TUNEL-positive nuclei (Fig. 9, e and i) and higher number of
NeuN-positive cells (Fig. 9, g and j). Together, these studies
showed that reducing Fer expression conferred neuroprotec-
tion to ischemic mouse brain.
In summary, these studies demonstrated that Sema3A
expression causes death of adult cortical neurons and that
blocking of Sema3A/NRP1 interaction is neuroprotective
both in vitro and in vivo. Mechanistically, NRP1-mediated neu-
ronal death was signaled directly through the cytoplasmic tyro-
sine kinase Fer.
DISCUSSION
The present study revealed two very important findings: 1)
the interaction between the chemorepulsive guidancemolecule
Sema3A and its receptor NRP1 is important in neuronal death
both in cultured cortical neurons and during cerebral ischemia
and 2) NRP1 directly interacts with the cytoplasmic non-recep-
tor tyrosine kinase Fer tomediate neurite damage and neuronal
death.
Although Sema/NRP’s functions during development have
been established (16, 18, 19, 43), their functions in the injured
adult brains are just starting to be understood. Although several
correlative studies have implicated semaphorins in a number of
FIGURE 7.Knocking downFer using RNAi provides neuroprotection against Sema3A-induced toxicity in
cortical neurons. Cultured 7 DIV cortical neurons were transfected with Fer RNAi or its control negative RNAi
at 1 g/well in a 24-well plate. After 36- and 48-h transfection, cells were collected for Western blotting to
demonstratedown-regulationof theexpressionof Fer as shown ina. GAPDHwasdetectedon theWesternblot
and used as a loading control. Band intensity wasmeasured using ImageJ, and the level of Fer was normalized
against the level of GAPDHandplotted inb. After 36 hof Fer small interference RNA transfection, neuronswere
challenged with 5g/ml Sema3A. PI-positive cells, indicated by long arrows, are shown in c–e. The number of
PI-positive cellswas counted andplotted after 24hof treatment (f). Neurite length, as indicatedby short arrows
in c–e, was also measured using ImageJ and plotted (g). At least 300 cells and their neurites were measured
from at least three independent experiments. Scale bar in c 50m. Error barsS.E. Statistical significance
was determined by one-way analysis of variance and further post hoc test for significant groups using Tukey’s
test with p 0.01.
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neurodegenerative diseases, including Alzheimer disease,
motor neuron degeneration, and injuries caused by cerebral
ischemia (16, 44), direct evidence showing Sema3A-mediating
neuronal death only comes from developmental evidence of
sensory neurons (22, 24–26). An antibody to Sema3A has been
shown to rescue retinal ganglion cells from cell death following
optic nerve axotomy in vivo (23), and blocking Sema3A using a
selective chemical inhibitor also enhanced nerve regeneration
of transacted spinal cord in adult mice (15). Altogether, it is
clear that inhibiting Sema3Amay provide a therapeutic poten-
tial against neuronal death. What is not clear, however, is
whether Sema3A function is occurring via NRP1 or NRP2, and
perhaps more importantly what specific intracellular signals
are being employed to mediate neuroprotection. In the present
study, we used a synthetic peptide blocking Sema3A/NRP1
interaction to show successful neuroprotection both in cul-
tured cortical neurons and in ischemic brains. The following
evidence derived from this study demonstrated a direct causal
relationship of Sema3A/NRP1 interaction with the death of
adult cortical neurons: 1) Sema3A protein caused axonal
growth cone collapse, axonal damage, and neuronal death pos-
itive to both PI and TUNEL staining; 2) NRP1 inhibitory pep-
tides, capable of preventing Sema3A/NRP1 interaction, pre-
vented Sema3A-mediated neuronal death. Most importantly,
Sema3A/NRP1 expression increased soon after ischemia reper-
fusion, and the NRP1 inhibitory peptides are neuroprotective
to the brain during ischemia, suggesting the Sema3A/NRP1
pathway contributes to the acute cascade of deleterious bio-
chemical events leading to ischemic neuronal death. Based on
the expression profile of Sema3A/NRP1, the present study only
examined the contribution of Sema3A/NRP1 after 24-h reper-
fusion. The long term benefit of blocking Sema3A/NRP1 inter-
action in ischemic brains remains to be investigated.
The MALDI-MS-based molecular imaging, although still in
its infancy as a method, proved to be a novel and precise way to
examine the integrity and distribution of the injected NRP1
inhibitory peptide (39, 45, 46). Using this method, we showed
that NRP1 inhibitory peptide was able to cross the parenchyma
following cerebral ischemia, presumably through the increased
permeability of the blood-brain barrier as indicated by the
higher level of signal in the ipsilateral side of the brain. NRP1
inhibitory peptide permeated a large area of the brain both in
the cortex and striatum based on the MALDI-MSI data, which
corresponds well with the area of MCAO-induced damage.
This approach allowed a direct visualization of the integrity and
distribution of the injected NRP1 inhibitor peptide and vali-
FIGURE 8. Knocking down Fer is neuroprotective against MCAO-induced neuronal death and improves neurological functions. a, schema of Fer RNAi
delivery tomouse brain. Fer RNAi or the control negative RNAiwas injected intomouse brains using stereotaxic injection. After 24, 48, 72, and 90 h of injection,
micewere killed andbrainwas collected for protein extraction andWesternblotting todetect changes in Fer expression level (b). Eachbrainwas separated into
the control side (c) and the injected side (I). Control mice were only subjected to skull surgery (labeled as Sham in b). The band intensities of Fer and GAPDH in
Fer RNAi-injectedmice brainsweremeasuredusing ImageJ software, and the average -fold changes of the ratio of Fer/GAPDHof two repeat experimentswere
plotted (c). Fer protein levelwas reducedbymore than1-fold in brains after 48- and72-h injectionwith Fer RNAi. Therefore,mice injectedwith Fer RNAi for 48h
were subjected to 1-hMCAO and followed by 24-h reperfusion. The experimental scheme is shown in d. Brain infarction size as indicated by the percentage of
decrease in TTC staining between the ipsilateral and contralateral side of the ischemic brain was determined using a spectrophotometric-based method to
detect soluble TTC color intensity extracted from the brain as described under “Experimental Procedures” (n 7 for each treatment) and the result is shown in
e. Forepaw grip strength test (f) and neurological deficit scores (g) were also performed before sacrificing the mice. Error barsS.E. Statistical significance
between theFerRNAi-treatedandcontrol negativeRNAi-treatedgroupswasdeterminedbyanon-parametricMann-WhitneyU testwith ** indicatingp0.01.
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dated the findings that the neuroprotection observed in the
NRP1 inhibitory peptide-treated brains was indeed due to the
presence of the peptide.
Sema3A negatively affects the efficacy of synaptic transmis-
sion evoked in the CA1 region of hippocampal slices (47). From
the current in vitro data, it is clear that NRP1 inhibitory pep-
tide-mediated neuroprotection was independent of NMDA
receptor-induced [Ca2]i. The ratiometric [Ca2]i measure-
ment showed that neither the NRP1 inhibitory peptide, nor
Sema3A protein alone, had any effect on neuronal [Ca2]i.
Most importantly, addition of NRP1 inhibitory peptide or
Sema3A protein did not affect NMDA receptor-mediated
[Ca2]i influx into neurons as shown in Fig. 5, thereby exclud-
ing the possibility that NRP1-mediated neuronal death may be
involved in coupling with NMDA receptors. These studies
prompted us to search for NRP1-specific downstream effec-
tors, ofwhich there are notmany knownpotential candidates to
choose from. The cytoplasmic domain of NRP1 is relatively
short, and it is believed that theC-terminal cytoplasmic domain
of NRP1 is unable to mediate functional responses to Sema3A
(48). However, surprisingly, based on an extended search for
NRP1-selective interacting proteins using a co-immunopre-
cipitation approach, we found that Fer kinase was selectively
associated with the NRP1 cytoplasmic domain. Most signifi-
cantly, blocking Sema3A/NRP1 interaction with the specific
synthetic inhibitory peptide reduced Fer binding to the NRP1
cytoplasmic domain. The reduction in Fer association with
NRP1 cytoplasmic domain correlated well with neuroprotec-
tion. Together, these findings explain the selectivity of NRP1 in
downstream signal transduction through Fer. Most interest-
ingly, down-regulation of Fer expression is neuroprotective
against Sema3A and cerebral ischemia as shown in Figs. 7–9,
respectively. The fact that Fer/ dorsal root ganglion neurons
are not responsive to Sema3A (42) strongly indicates a role of
Fer in neuronal response to Sema3A. This study, for the first
time, clearly demonstrated that Fer is an important part of the
death signal transduction pathway in adult cortical neurons. It
remains unclear at this stage as to the downstream effectors
for NRP1/Fer-mediated neuronal death, and they are cur-
rently being investigated. Possible candidates include collap-
sin response mediator proteins, which, we have previously
shown, are important in mediating ischemic neuronal death
(11, 33, 49).
In summary, the present study demonstrated a pivotal role for
Sema3A/NRP1 in modulating the death of adult cortical neurons
throughdirect and selective interactionwith the cytoplasmicnon-
receptor tyrosine kinase Fer. Blocking Sema3A/NRP1 interaction
is neuroprotective even during a relatively acute phase of stroke,
firmly establishing Sema3A/NRP1/Fer as part of the damage
response in acute stroke-induced neuronal death. Although the
long term benefit of blocking Sema3A/NRP1 remains to be
established, understanding this interaction provided a novel
avenue to target non-NMDA receptors for development of
therapeutics against stroke-induced brain damage.
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FIGURE 9. Knocking down Fer expression reduces the number of TUNEL-
positive neurons in ischemic mouse brain.Mice injected with Fer RNAi for
48 h were subjected to 1-h MCAO, and followed by 24-h reperfusion. Mouse
brains were subjected to frozen serial sectioning and immunostaining for
TUNEL (a, b, e, and f; solid arrows in a indicate TUNEL-positive nuclei) and
NeuN (c, d, g, and h; open arrows in c indicate NeuN-positive neurons). High
resolution digital images of brain sections were taken, and the numbers of
TUNEL- andNeuN-positive cellswere countedon images covering the area of
a 40 objective lens from the microscope (i and j). Scale bar 80 m. Error
bars  S.E. Statistical significance was determined by a non-parametric
Mann-Whitney U test with ** indicating p  0.01 between the treated and
control-treated groups using data from at least three independent repeats.
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